VYRE Network Partners with Recurrent Ventures to launch “We Are The Mighty”, a Military Lifestyle Focused Channel
19. März 2024 08:22 ET
|
VYRE Network
VYRE Network, is pleased to announce its partnership with Recurrent Ventures to create, curate and distribute military lifestyle video content.
Black Book Enhances EV Values with Recurrent Battery Insights
23. Januar 2024 09:00 ET
|
Recurrent Auto; Black Book
LAWRENCEVILLE, Ga., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Black Book today introduced the industry's first electric vehicle (EV) valuations, dubbed Battery Adjusted Values™, which incorporate battery...
Recurrent Shows EV Prices Soared in 2021, Benefitting Tesla the Most
10. Januar 2022 10:30 ET
|
Recurrent Auto
SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Recurrent, the car industry’s leading analyst of electric vehicle (EV) battery health, today released its Q1 2022 Used Electric Car Buying Report. Most...
Data From Recurrent Shows the Substantial Impact Winter Weather Has on EV Batteries
14. Dezember 2021 10:30 ET
|
Recurrent Auto
SEATTLE, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Recurrent, the car industry’s leading analyst of electric vehicle (EV) battery health, today released new winter range data on the impact that freezing...
Data From Recurrent Reveals 30% of Owners of Recalled Chevy Bolts Are Not Following General Motors Recall Guidelines for Vehicle Charging
25. August 2021 12:00 ET
|
Recurrent Auto
SEATTLE, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Recurrent, the car industry’s only analyst of electric vehicle (EV) battery health, today released new data analyzing the actions of more than 1,000 Chevy...
Recurrent Introduces New Guides Analyzing Battery Range on Specific Makes and Models of Pre-Owned Electric Vehicles
13. Juli 2021 11:01 ET
|
Recurrent Auto
SEATTLE, July 13, 2021 (GLOBE NEWSWIRE) -- Recurrent, the car industry’s analyst of electric vehicle battery health, today announces the release of the first-ever electric vehicle battery guides for...
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901
29. Juli 2019 08:00 ET
|
VBI Vaccines, Inc.
— Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded...